Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Cardiovascular Medicine
Published in: Current Treatment Options in Cardiovascular Medicine 11/2015

01-11-2015 | Pediatric Congenital Heart Disease (G Singh, Section Editor)

Fontan Liver Disease: Review of an Emerging Epidemic and Management Options

Authors: Elisa Bradley, MD, Benjamin Hendrickson, MD, Curt Daniels, MD

Published in: Current Treatment Options in Cardiovascular Medicine | Issue 11/2015

Login to get access

Opinion statement

Adults with complex congenital heart disease that resulted in a Fontan procedure frequently experience late cardiac failure. Increasingly, liver disease is recognized as an important complication of single-ventricle anatomy and Fontan physiology; however, there is no consensus regarding liver evaluation in this population. Here, we review what is known about liver disease in this unique group and propose screening and prevention measures. We also review controversial treatment areas including assist devices and transplantation, with a review of outcomes in isolated heart and combined heart-liver transplant.
Literature
1.
2.
3.
Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg. 2005;129:1348–52.CrossRefPubMed
4.
5.
Friedrich-Rus M et al. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers. J Thorac Cardiovasc Surg. 2008;135:560–7.CrossRef
6.
Rychik J, Veldtman G, Rand E, Russo P, Rome JJ, Krok K, et al. The precarious state of the liver after a Fontan operation: a summary of a multidisciplinary symposium. Pediatr Cardiol. 2012;33:1001–12.PubMedCentralCrossRefPubMed
7.
Wu FM, Ukomadu C, Odze RD, Valente AM, Mayer JE, Earing MG. Liver disease in the patient with Fontan circulation. Congenit Heart Dis. 2011;6:190–201.CrossRefPubMed
8.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, TerBorg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.CrossRefPubMed
9.
Lemmer JH, Coran AG, Behrendt DM, Heidelberger KP, Stern AM. Liver fibrosis (cardiac cirrhosis) five years after modified Fontan operation for tricuspid atresia. J Thorac Cardiovasc Surg. 1983;86:757–60.PubMed
10.
Kendall T, Stedman B, Hacking N, Haw M, Vettukattill J, Salmon A, et al. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphologic review. J Clin Pathol. 2008;61:504–8.CrossRefPubMed
11.
Schwartz MC, Sullivan L, Cohen MS, Russo P, John AS, Guo R, et al. Hepatic pathology may develop before the Fontan operation in children with functional single ventricle: an autopsy study. J Thorac Cardiovasc Surg. 2012;143:904–9.CrossRefPubMed
12.
Schwartz MC, Sullivan LM, Glatz AC, Rand E, Russo P, Goldberg AC, et al. Portal and sinusoidal fibrosis are common on liver biopsy after Fontan surgery. Pediatr Cardiol. 2013;34:135–2.CrossRefPubMed
13.
Johnson JA, Cetta F, Graham RP, Smyrk TC, Driscoll DJ, Phillips SD, et al. Identifying predictors of hepatic disease in patients after the Fontan operation: a postmortem analysis. J Thorac Cardiovasc Surg. 2013;146:140–5.CrossRefPubMed
14.
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.CrossRefPubMed
15.
Park GJ, Lin BP, Ngu MC, et al. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol. 2000;15:386–90.CrossRefPubMed
16.
Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93:44–8.CrossRefPubMed
17.
Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relation Cirrhosis Gastroenterol. 1988;95:734–9.
18.
Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986–92.CrossRefPubMed
19.
Bonacini M, Hadi G, Govindarajan S, et al. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1997;92:1302–4.PubMed
20.
Pohl A, Behling C, Oliver D, et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001;96:3142–6.CrossRefPubMed
21.
Heuman DM, Mihas AA, Habib A, et al. MELD-XI: a rational approach to “sickest first” liver transplantation in cirrhotic patients require anticoagulant therapy. Liver Transpl. 2007;13:30–7.CrossRefPubMed
22.
Kendall TJ, Stedman B, Hacking N, Haw M, Vettukattill JJ, Salmon AP, et al. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphologic study. J Clin Pathol. 2008;61:504–8.CrossRefPubMed
23.
Baek JS, Bae EJ, Ko JS, Kim GB, Kwon BS, Lee SY, et al. Late hepatic complications after Fontan operation; non-invasive markers of hepatic fibrosis and risk factors. Heart. 2010;96:1750–5.CrossRefPubMed
24.
Furukawa T, Akimoto K, Ohtsuki M, Sato K, Suzuki M, Takahashi K, et al. Pediatr Int. 2011;53:980–4.CrossRefPubMed
25.
Guha IN, Bokhandi S, Ahmad Z, Sheron N, Cope R, Marshall C, et al. Structural and functional uncoupling of liver performance in Fontan circulation. Int J Cardiol. 2013;164:77–81.CrossRefPubMed
26.••
Ginde S, Hohenwalter MD, Foley WD, Sowinski J, Bartz PJ, Venkatapuram S, et al. Noninvasive assessment of liver fibrosis in adult patients following the Fontan procedure. Congent Heart Dis. 2012;7:235–42. The first publication to show imaging evidence of fibrosis and correlation to clinical findings/lab tests in adult Fontan patients.CrossRef
27.
Elder RW, McCabe NM, Hebson C, Veledar E, Romero R, Ford RM, et al. Features of portal hypertension associated with major adverse events in Fontan patients: the VAST study. Int J Cardiol. 2013;168:3764–9.PubMedCentralCrossRefPubMed
28.
Kaulitz R, Haber P, Sturm E, Schafer J, Hofbeck M. Serial evaluation of hepatic function profile after Fontan operation. Herz. 2014;39:98–104.CrossRefPubMed
29.
Wallihan DB, Podberesky DJ. Hepatic pathology after Fontan palliation: spectrum of imaging findings. Pediatr Radiol. 2013;43:330–8.CrossRefPubMed
30.
Kutty SS, Peng Q, Danford DA, Fletcher SE, Perry D, Talmon GA, Scott C, Kuger JD, Dunca KF, Quiros-Tejeira RE, Kutty S. Increased hepatic stiffness as consequence of high hepatic afterload in the Fontan circulation: a vascular Doppler and elastography study. Hepatology. 2014; 251–260.
31.
Ofei SY, Gariepy C, Hanje J, Sisk T, Daniels CJ, Zaidi AN. Liver fibrosis in adults with Fontan palliation: do common screening studies predict disease severity? Int J Cardiol. 2015;181:174–1745.CrossRefPubMed
32.
Suraj SD, Wallihan DB, Venkatesh SK, Ehman RL, Campbell KM, Sticka J, et al. Magnetic resonance elastography of the liver in patients status-post Fontan procedure. Feasib Prelim Res. 2014;9:7–14.
33.
Wallihan DB, Podberesky DJ, Marino BS, Sticka JS, Suraj S. Relationship of MR elastography determined liver stiffness with cardiac function after Fontan palliation. J Mag Resonance Imag. 2014;40:1328–35.CrossRef
34.
Won Yoo B, Choi JY, Eun LY, Park HK, Park YH, Kim SU. Congestive hepatopathy after Fontan operation and related factors assessed by transient elastography. J Thorac Cardiovasc Surg. 2014;148:1498–505.CrossRef
35.••
Wu FM, Opotowsky AR, Raza R, Harney S, Ukomadu C, Landzberg MJ, et al. Transient elastography may identify Fontan patients with unfavorable hemodynamics and advanced hepatic fibrosis. Congenit Heart Dis. 2014;9:438–47. The largest and most comprehensive analysis of clinical, imaging, and pathologic liver findings in adult Fontan patients.CrossRefPubMed
36.
Wu FM, Jonas MM, Opotowsky AR, Harmon A, Raza R, Ukomadu C, et al. Portal and centrilobular hepatic fibrosis in Fontan circulation and clinical outcomes. J Heart Lung Transplant. 2015;34:883–91.CrossRefPubMed
37.
Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013;159:349–57.CrossRefPubMed
38.
39.
Cox DA, Ginde S, Tweddell JS, Earing MG. Outcomes of a hepatitis C screening protocol in at-risk adults with prior cardiac surgery. World J Pediatr Congenit Heart Surg. 2014;4:503–6.CrossRef
40.
Wang A, Book WM, McConnell M, Lyle T, Rodby K, Mahle WT. Prevalence of hepatitis C infection in adult patients who underwent congenital heart surgery prior to screening in 1992. Am J Cardiol. 2007;100:1307–9.CrossRefPubMed
41.
Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg. 2005;129:1348–52.CrossRefPubMed
42.
Bryant T, Ahmad Z, Millward-Sadler H, et al. Arterialised hepatic nodules in the arterialised hepatic nodules in the Fontan circulation: hepatico-cardiac interactions. Int J Cardiol. 2011;151:268–72.CrossRefPubMed
43.
Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–22.PubMed
44.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421–30.CrossRefPubMed
45.
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy: AASLD position paper. Hepatology. 2009;49:1017–44.CrossRefPubMed
46.
Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond). 2012;123:225–39.CrossRef
47.
Riemer RK, Amir G, Reichenbach SH, Reinhartz O. Mechanical support of total cavopulmonary connection with an axial flow pump. J Thorac Cardiovasc Surg. 2005;130:351–4.CrossRefPubMed
48.
Newcomb AE, Negri JC, Brizard CP, d’Udekem Y. Successful left ventricular assist device bridge to transplantation after failure of a Fontan revision. J Heart Lung Transplant. 2006;25:365–57.CrossRefPubMed
49.
Prêtre R, Haussler A, Bettex D, Genoni M. Right-sided univentricular cardiac assistance in a failing Fontan circulation. Ann Thorac Surg. 2008;86:1018–820.CrossRefPubMed
50.
Calvaruso DF, Ocello S, Salviato N, Guardì D, Petruccelli DF, Rubino A, et al. Implantation of a Berlin Heart as single ventricle by-pass on Fontan circulation in univentricular heart failure. ASAIO J. 2007;53:e1–2.CrossRefPubMed
51.
Rossano JW, Goldberg DJ, Fuller S, Ravishankar C, Montenegro LM, Gaynor JW. Successful use of the total artificial heart in the failing Fontan circulation. Ann Thorac Surg. 2014;97:1438–40.CrossRefPubMed
52.
Rossano JW, Woods RK, Berger S, Gaynor JW, Ghanayem N, Morales DL, et al. Mechanical support as failure intervention in patients with cavopulmonary shunts (MFICS): rationale and aims of a new registry of mechanical circulatory support in single ventricle patients. Congenit Heart Dis. 2013;8:182–6.CrossRefPubMed
53.
Jabbar AA, Franklin WJ, Simpson L, Civitello AB, Delgado 3rd RM, Frazier OH. Improved systemic saturation after ventricular assist device implantation in a patient with decompensated dextro-transposition of the great arteries after the Fontan procedure. Tex Heart Inst J. 2015;42:40–3.PubMedCentralCrossRefPubMed
54.
Tsuda S, Sasaki T, Maeda K, Riemer RK, Reichenbach SH, Reinhartz O. Recovery during mid-term mechanical support of Fontan circulation in sheep. ASAIO J. 2009;55:406–11.CrossRefPubMed
55.
Carney EL, Clark JB, Myers JL, Peterson R, Wilson RP, Weiss WJ. Animal model development for the Penn State pediatric ventricular assist device. Artif Organs. 2009;33:953–7.PubMedCentralCrossRefPubMed
56.
Tuzun E, Roberts K, Cohn WE, et al. In vivo evaluation of the HeartWare centrifugal ventricular assist device. Tex Heart Inst J. 2007;34:406.PubMedCentralPubMed
57.
58.
Derk G, Laks H, Biniwale R, Patel S, De LaCruz K, Mazor E, et al. Novel techniques of mechanical circulatory support for the right heart and Fontan circulation. Int J Cardiol. 2014;176:828–32.CrossRefPubMed
59.
Voeller RK, Epstein DJ, Guthrie TJ, Gandhi SK, Canter CE, Huddleston CB. Trends in the indications and survival in pediatric heart transplants: a 24-year single-center experience in 307 patients. Ann Thorac Surg. 2012;94:807–16.CrossRefPubMed
60.
Davies RR, Sorabella RA, Yang J, Mosca RS, Chen JM, Quaegebeur JM. Outcomes after transplantation for ‘failed’ Fontan: a single-institution experience. J Thorac Cardiovasc Surg. 2012;143:1183–92.CrossRefPubMed
61.
Lamour JM, Kanter KR, Naftel DC, Chrisant MR, Morrow WR, Clemson BS, et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol. 2009;54:160–5.CrossRefPubMed
62.
Bhama JK, Shulman J, Bermudez CA, Bansal A, Ramani R, Teuteberg JJ, et al. Heart transplantation for adults with congenital heart disease: results in the modern era. J Heart Lung Transplant. 2013;32:499–504.CrossRefPubMed
63.
Bernstein D, Naftel D, Chin C, Addonizio LJ, Gamberg P, Blume ED, et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation. 2006;114:273–80.CrossRefPubMed
64.
Lamour JM, Addonizio LJ, Galantowicz ME, Quaegebeur JM, Mancini DM, Kichuk MR, et al. Outcome after orthotopic cardiac transplantation in adults with congenital heart disease. Circulation. 1999;100(19 Suppl):II200–5.PubMed
65.
Davies RR, Russo MJ, Yang J, Quaegebeur JM, Mosca RS, Chen JM. Listing and transplanting adults with congenital heart disease. Circulation. 2011;123:759–67.CrossRefPubMed
66.
Michielon G, van Melle J, Wolff D, DiCarolo D, Jacobs JP, Mattila IP, et al. Favourable mid-term outcome after heart transplantation for late Fontan failure. 2014;1–7.
67.
Kanter KR, Mahle WT, Vincent RN, Berg AM, Kogon BE, Kirshbom PM. Heart transplantation in children with a Fontan procedure. Ann Thorac Surg. 2011;91:823–30.CrossRefPubMed
68.
Chokshi A, Cheema FH, Schaefle KJ, Jiang J, Collado E, Shahzad K, et al. Hepatic dysfunction and survival after orthotopic heart transplantation: application of the MELD scoring system for outcome prediction. J Heart Lung Transplant. 2012;31:591–600.PubMedCentralCrossRefPubMed
69.
Robinson JA, Driscoll DJ, O’Leary PW, Burkhart HM, Dearani JA, Daly RC, et al. Cardiac and multiorgan transplantation for end-stage congenital heart disease. Mayo Clin Proc. 2011;89:478–83.CrossRef
70.
Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the AASLD and the American Society of Transplantation.
71.
Atluri P, Gaffey A, Howard J, Phillips E, Goldstone AB, Hornsby N, et al. Combined heart and liver transplantation can be safely performed with excellent short- and long-term results. Ann Thorac Surg. 2014;98:858–62.CrossRefPubMed
72.
Raichlin E, Ym JY, Duncan KF, Dumitru I, Lowes BD, Moulton M, et al. Combined heart and liver transplantation against positive cross-match for patient with hypoplastic left heart syndrome. 2014;98:e100-102.
73.
Hollander SA, Reinhartz O, Maeda K, Hurwitz M, Rosenthal DN, Bernstein D. Intermediate-term outcomes after combined heart-liver transplantation in children with a univentricular heart. J Heart Lung Transplant. 2013;32:368–70.CrossRefPubMed
74.
Nagpal AD, Chamogeorgakis T, Shafii AE, Hanna M, Miller CM, Fung J, et al. Combined heart and liver transplantation: the Cleveland Clinic experience. Ann Thorac Surg. 2013;95:179–82.CrossRefPubMed
75.
Vallabhajosyula P, Komlo C, Wallen TJ, Olthoff K, Pochettino A. Combined heart-liver transplant in a situs-ambiguous patient with failed Fontan physiology. J Thorac and Cardiovasc Surg. 2012;145:e39–40.CrossRef
76.
Vallabhajosyula P, Komlo C, Molina M, Roche L, Kim Y, Goldberg L, et al. Combined heart-liver transplantation (HLT) for failed single ventricle/Fontan physiology. J Heart Lung Transplant. 2012;31:S112.CrossRef
77.
Hill AL, Maeda K, Bonham CA, Concepcion W. Pediatric combined heart-liver transplantation performed en block: a single-center experience. Pediatr Transplant. 2012;16:392–7.CrossRefPubMed
78.
Horai T, Bhama JK, Fontes PA, Toyoda Y. Combined heart and liver transplantation in a patient with situs ambiguous. Ann Thorac Surg. 2011;91:600–1.CrossRefPubMed
79.
Te HS, Anderson AS, Millis M, Jeevanandam V, Jensen DM. Current state of combined heart-liver transplantation in the United States. J Heart Lung Transplant. 2008;27:753–9.CrossRefPubMed
80.
Cannon RM, Hughes MG, Jones CM, Eng M, Marvin MR. A review of the United States experience with combined heart-liver transplantation. Transpl Int. 2012;12:1223–8.CrossRef
81.
Raichlin E, Daly RC, Rosen CB, McGregor CG, Charlton MR, Frantz RP, et al. Combined heart and liver transplantation: a single center experience. Transplantation. 2009;88:219–25.CrossRefPubMed
82.•
Simpson KE, Esmaeeli A, Khanna G, White F, Turnmelle Y, Eghtesady P, et al. Liver cirrhosis in Fontan patients does not affect 1-year post-heart transplant mortality or markers of liver function. J Heart Lung Transplant. 2014;33:170–7. The only study evaluating liver function post isolated heart transplant in Fontan patients.PubMedCentralCrossRefPubMed
83.••
Farr M, Mitchell J, Lippel M, Kato TS, Jin Z, Ippolito P, et al. Combination of liver biopsy with MELD-XI scores for post-transplant outcome prediction in patients with advanced heart failure and suspected liver dysfunction. J Heart Lung Transplant. 2015;34:873–82. The first and only study proposing a risk score inclusive of pathologic and clinical markers of liver disease in patients who have undergone combined heart liver transplant.CrossRefPubMed
Metadata
Title
Fontan Liver Disease: Review of an Emerging Epidemic and Management Options
Authors
Elisa Bradley, MD
Benjamin Hendrickson, MD
Curt Daniels, MD
Publication date
01-11-2015
Publisher
Springer US
Published in
Current Treatment Options in Cardiovascular Medicine / Issue 11/2015
Print ISSN: 1092-8464
Electronic ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-015-0412-z

Other articles of this Issue 11/2015

Current Treatment Options in Cardiovascular Medicine 11/2015 Go to the issue

Pediatric Congenital Heart Disease (G Singh, Section Editor)

Contraception and Pregnancy Planning in Women With Congenital Heart Disease

Pediatric Congenital Heart Disease (G Singh, Section Editor)

Adult With Congenital Heart Disease in Developing Country: Scope, Challenges and Possible Solutions

Valvular Heart Disease (J Passeri, Section Editor)

Minimally Invasive Mitral Valve Surgery via Mini-Thoracotomy: Current Update

Pediatric Congenital Heart Disease (G Singh, Section Editor)

Dynamic Evaluation of Coronary Anomalies Originating from the Opposite Sinus of Valsalva (ACAOS)

Imaging (J Hung, Section Editor)

Role of Cardiac MRI in the Assessment of Cardiomyopathy

Imaging (J Hung, Section Editor)

Assessment of Aortic Valve Disease: Role of Imaging Modalities

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits